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Wadkin JC, Patten DA, Kamarajah SK, Shepherd EL, No-
vitskaya V, Berditchevski F, Adams DH, Weston CJ, Shetty S.
CD151 supports VCAM-1-mediated lymphocyte adhesion to liver
endothelium and is upregulated in chronic liver disease and hep-
atocellular carcinoma. Am J Physiol Gastrointest Liver Physiol
313: G138 –G149, 2017. First published May 4, 2017; doi:10.1152/
ajpgi.00411.2016.—CD151, a member of the tetraspanin family of
receptors, is a lateral organizer and modulator of activity of several
families of transmembrane proteins. It has been implicated in the
development and progression of several cancers, but its role in
chronic inflammatory disease is less well understood. Here we
show that CD151 is upregulated by distinct microenvironmental
signals in a range of chronic inflammatory liver diseases and in
primary liver cancer, in which it supports lymphocyte recruitment.
CD151 was highly expressed in endothelial cells of the hepatic
sinusoids and neovessels developing in fibrotic septa and tumor
margins. Primary cultures of human hepatic sinusoidal endothelial
cells (HSECs) expressed CD151 at the cell membrane and in
intracellular vesicles. CD151 was upregulated by VEGF and
HepG2 conditioned media but not by proinflammatory cytokines.
Confocal microscopy confirmed that CD151 colocalized with the
endothelial adhesion molecule/immunoglobulin superfamily mem-
ber, VCAM-1. Functional flow-based adhesion assays with pri-
mary human lymphocytes and HSECs demonstrated a 40% reduc-
tion of lymphocyte adhesion with CD151 blockade. Inhibition of
lymphocyte adhesion was similar between VCAM-1 blockade and a
combination of CD151/VCAM-1 blockade, suggesting a collaborative
role between the two receptors. These studies demonstrate that CD151
is upregulated within the liver during chronic inflammation, where it
supports lymphocyte recruitment via liver endothelium. We propose
that CD151 regulates the activity of VCAM-1 during lymphocyte
recruitment to the human liver and could be a novel anti-inflammatory
target in chronic liver disease and hepatocellular cancer prevention.
NEW & NOTEWORTHY Chronic hepatitis is characterized by
lymphocyte accumulation in liver tissue, which drives fibrosis and
carcinogenesis. Here, we demonstrate for the first time that the
tetraspanin CD151 supports lymphocyte adhesion to liver endothe-
lium. We show that CD151 is upregulated in chronic liver disease and
hepatocellular carcinoma (HCC) and is regulated on endothelium by
tissue remodeling and procarcinogenic factors. These regulatory and
functional studies identify CD151 as a potential therapeutic target to
treat liver fibrosis and HCC.
tetraspanin 24; hepatic sinusoidal endothelial cells; lymphocyte re-
cruitment
CHRONIC INFLAMMATORY LIVER DISEASE can progress to end-stage
liver failure and also promotes a protumorigenic environment,
leading to hepatocellular carcinoma (HCC) (6, 10, 13, 26).
Liver disease is a major global health burden, and HCC is now
the second leading cause of cancer-related deaths worldwide
(19). Inflammatory liver diseases are characterized by a
chronic lymphocytic infiltrate, which drives the development
of fibrosis and cirrhosis (21, 31). In contrast to other organs, in
which extravasation usually occurs in postcapillary venules,
the majority of lymphocyte recruitment to the liver occurs
within the hepatic sinusoids, which are lined by highly spe-
cialized hepatic sinusoidal endothelial cells (HSECs) (9, 37).
Control of the inflammatory response by HSECs through
regulation of recruitment of recirculating lymphocytes is there-
fore central to tissue homeostasis, and any perturbation of
endothelial cell function may drive the liver phenotype
toward cirrhosis or tumorigenesis (6, 26). The low-shear
hepatic sinusoids provide a unique environment for lympho-
cyte recruitment, in which HSECs display distinct differ-
ences in adhesion molecule expression, such as a lack of
expression of P- and E-selectin, compared with conven-
tional vascular endothelial cells (1). Within the hepatic
sinusoids, lymphocyte adhesion is mediated through other
adhesion proteins, such as ICAM-1 and VCAM-1, in addi-
tion to more specialized receptors, such as vascular adhesion
protein-1 (VAP-1) and stabilin-1 (23, 33, 36).
Another family of proteins that may also play a role in
modulating hepatic inflammation is the tetraspanin family.
Tetraspanins comprise a large group of cell membrane proteins
with low-sequence homology but conserved secondary and
tertiary protein structures, with 33 distinct family members
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having been identified in mammals (11). They are character-
ized by four transmembrane domains delimiting three short
intracellular regions and two extracytoplasmic loops, a small
extracellular loop (EC1) and a large extracellular loop (EC2).
CD151, also known as tetraspanin 24 (Tspan24), has previ-
ously been shown to cluster at the cell membrane in tetraspa-
nin-enriched microdomains and is widely expressed in several
cell types, including epithelial, endothelial, muscle, and hema-
topoietic cells (3, 20). In endothelial cells, CD151 was pro-
posed to act as a lateral organizer and modulator of activities of
transmembrane proteins, including ICAM-1 and VCAM-1,
forming endothelial adhesive platforms (EAPs) (24). EAPs
have been shown to play an essential role in the spatial
organization of the membrane and in the recruitment of
ICAM-1 and VCAM-1 toward the contact area with adherent
leucocytes, thus regulating endothelial cell adhesiveness (5).
Previous studies have demonstrated that CD151 contributes to
the adhesion of leukocytes to human umbilical vein endothelial
cells via EAPs (4). Our aim was to study whether CD151
contributed to lymphocyte recruitment to the human liver and
whether it could be a novel target to treat chronic inflammatory
liver disease and HCC.
In this study, we characterize the expression of CD151 in
human liver tissue from a range of chronic liver diseases and
in HCC. We show that CD151 is predominantly expressed on
endothelial cells in the human liver. CD151 protein expression
was found to be upregulated at sites of fibrosis in chronic liver
diseases and overexpressed in HCC compared with normal
liver tissue. We also demonstrate that HSECs and neovessels
within the fibrotic septa account for the majority of CD151
expression observed in diseased livers in vivo. Isolated HSECs
maintain strong expression of CD151, enabling studies into the
regulation and function of CD151. We show that surface
expression of CD151 in isolated HSECs can be upregulated by
mimicking a tumorigenic environment and that CD151 colo-
calizes with VCAM-1 in stimulated HSECs. Finally, we con-
firm that CD151 mediates lymphocyte adhesion to primary
HSECs in flow-based adhesion assays in a VCAM-1-depen-
dent manner.
MATERIALS AND METHODS
Human tissue and blood samples. All tissue and blood samples
were obtained from the Queen Elizabeth Hospital, Birmingham,
United Kingdom. Sections of normal human liver tissue were acquired
from rejected donor liver tissue or from marginal tissue of hepatic
resections. Diseased liver and HCC tissue was sourced from explanted
livers during transplantation procedures. Tissue and blood samples
from patients were obtained with written, informed consent and with
local ethics committee approval (LREC reference 06/Q2702/61 South
Birmingham, Birmingham, UK and 04/Q2708/41 South Birmingham,
Birmingham, UK).
Immunohistochemistry. Acetone-fixed, frozen liver sections (5 m
thick) were taken from normal liver, chronically diseased liver, and
HCC tumor tissue, with at least four individual cases studied for each
group. For immunohistochemical staining, endogenous peroxide ac-
tivity was blocked with 0.3% H2O2 in methanol. The sections were
then blocked for nonspecific antibody binding by using a 2 casein
solution in PBS (from 10 stock; Vector) for 20 min. Slides were
then incubated with primary antibody (mouse monoclonal anti-human
CD151 IgG1, clone IIG5a; Abd Serotec; 5 g/ml) or isotype-matched
control (mouse IgG1-negative control, clone DAK-GO1; Dako; 5
g/ml), diluted in PBS for 60 min at room temperature. The slides
were then washed in PBS/0.1% Tween (PBST) and incubated with
ImmPRESS Universal anti-mouse IgG reagent (Vector Laboratories)
for 30 min at room temperature. Subsequently, slides were again
washed with PBST and incubated with DAB Substrate (Vector) for 2
min. Sections were washed in tap water, counterstained with hema-
toxylin (Mayers; Pioneer Research Chemicals), dehydrated with se-
quential washes in alcohol and xylene, and finally mounted with DPX
(phthalate-free) mounting medium (Cell Path). Images were acquired
and analyzed on a Zeiss Axioscope microscope with concurrent
Axiovision software (Carl Zeiss). Semiquantificative analysis of pos-
itively stained areas was performed with ImageJ software.
Immunofluorescence. For immunofluorescent staining, acetone-
fixed, frozen liver sections were initially blocked with 10% goat
serum (GIBCO by Life Technologies) and 2 casein in PBS for 20
min at room temperature. Primary antibodies, or the relevant isotype-
matched negative control, diluted in blocking buffer, were added and
incubated for 60 min at room temperature. After being washed in
PBST, the slides were incubated with the relevant fluorescence-
conjugated goat anti-mouse secondary antibodies diluted in blocking
buffer for 30 min. The sections were then washed again in PBST, and
300 nM DAPI (Sigma-Aldrich) was added to each section for 2 min
before the slides were mounted in aqueous Fluorescent Mounting
Medium (Dako) and imaged. Where colocalization staining was
performed with two mouse IgG1 primary antibodies, CD151-targeting
primary antibody and respective secondary antibody were added first,
followed by extensive washing with PBST before sequential addition
of the next mouse IgG1 primary and respective secondary antibody.
Antibodies. Antibodies used, including concentration and source,
are listed in Table 1.
Isolation of nonparenchymal cells. A sample (30–50 g) of human
liver tissue, taken from diseased livers (alcoholic liver disease, pri-
mary sclerosing cholangitis, primary biliary cholangitis) and normal
liver resection margins, was mechanically chopped before being
enzymatically digested with collagenase type 1A (10 mg/ml; Sigma-
Aldrich). The resultant digest was filtered through a fine muslin mesh
then centrifuged over a 33/77% (wt/vol) Percoll (GE Healthcare Life
Sciences) density gradient for 20 min at 800 g. The nonparenchymal
cell fraction was removed from the gradient interface, and cell
populations were purified by immunomagnetic selection. Human
epithelial antigen (HEA-125) antibody (50 g/ml; Progen Biotech-
nik), along with conjugated with goat anti-mouse monoclonal anti-
body (mAb) Dynabeads (Invitrogen), was used to select biliary
epithelial cells (BECs). HSECs were isolated by positive selection
with anti-CD31 antibody-conjugated bead (Life Technologies) and
cultured on rat-tail collagen-coated plastic ware. The remaining neg-
atively selected activated liver myofibroblasts (aLMFs) were plated
out into tissue culture plastic (16).
Isolation of human hepatic stellate cells. Hepatic stellate cells
(HSCs) were isolated from nonfibrotic liver tissue using pronase/
collagenase digestion and buoyancy centrifugation, as previously
described (16). Viability was tested by Trypan blue (Sigma-Aldrich)
exclusion, and endogenous vitamin A autofluorescence was sugges-
tive of a purity 90%.
Isolation of primary human hepatocytes. Primary human hepato-
cytes (PHHs) were isolated using a modified two-stage collagenase
procedure, as described previously (8).
Fluorescein isothiocyanate-labeled formaldehyde-denatured serum
albumin uptake assay. Fluorescein isothiocyanate-labeled formalde-
hyde-denatured serum albumin (FITC-FSA; Sigma-Aldrich) was di-
luted to 10 g/ml in endothelial medium and added to HSEC mono-
layers grown in rat-tail collagen-coated 0.4 channel -Slides VI
(Ibidi). After 15 min, the channels were washed three times in PBS,
the cells were fixed with 4% paraformaldehyde solution for 10 min,
washed with PBS, and DAPI stained to identify nuclei, and FITC
positivity was analyzed using a Carl Zeiss LSM780 Zen Confocal
microscope (Carl Zeiss) and LSM software. Control cells were incu-
bated with the same medium without the addition of FITC-FSA.
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Purity was assessed as the percentage of FITC-positive plated cells
taken from six random fields.
Cell lines and primary cell maintenance. HepG2 cells were cul-
tured in DMEM (GIBCO by Life Technologies) with 10% heat-
inactivated FCS (ThermoFisher Scientific). BECs were cultured in
Hams F12 Nutrient Mixture (GIBCO by Life Technologies) with the
following supplements: 10% heat-inactivated human serum (TCS
Biosciences), hepatocyte growth factor (HGF; 10 ng/ml; Peprotech),
epidermal growth factor (EGF; 10 ng/ml; Peprotech), hydrocortisone
(2 g/ml; Sigma-Aldrich), cholera toxin (10 ng/ml; Sigma-Aldrich),
tri-iodo-thyronine (2 nM; Sigma-Aldrich), insulin (0.124 U/ml;
Sigma-Aldrich), 100 U/ml penicillin, 100 g/ml streptomycin, 2 mM
L-glutamine [penicillin-streptomycin-glutamine (100); GIBCO by
Life Technologies]. HSECs were maintained in human endothelial
serum-free media (SFM) with 10% human serum, 100 U/ml penicil-
lin, 100 g/ml streptomycin, 2 mM L-glutamine (all GIBCO by Life
Technologies), 10 ng/ml of HGF (Peprotech), and 10 ng/ml VEGF
(Peprotech). HSCs and aLMFs were cultured in Dulbecco’s Modified
Eagle medium (DMEM; GIBCO by Life Technologies) with 16%
heat-inactivated FCS (ThermoFisher Scientific) and 100 U/ml peni-
cillin, 100 g/ml streptomycin, and 2 mM L-glutamine (all GIBCO by
Life Technologies).
Quantitative real-time PCR. A sample (~20 mg) of liver tissue was
homogenized in RLT buffer (QIAGEN) with -mecaptoethanol (Sigma-
Aldrich), on a gentleMACS Dissociator (Miltenyi Biotec).
RNA extraction was then performed using the RNeasy Mini Kit
(QIAGEN) following the manufacturer’s protocol with column
DNaseI digestion. Alternatively, RNA was extracted from highly pure
cell populations isolated from a range of livers, including alcoholic
liver disease, primary sclerosing cholangitis, primary biliary cirrhosis,
and nonalcoholic steatohepatitis. Additionally, HSECs were grown to
confluence in six-well plates (Corning CoStar), stimulated for 24 h
(see Stimulation of HSECs below), then harvested by direct cell lysis
through the addition of RLT buffer. RNA extraction was performed
with the use of an RNeasy Micro Kit (QIAGEN), following the
manufacturer’s protocol as above.
Following RNA extraction, RNA concentration and purity were
determined by use of a Nanophotometer (Implen), and cDNA was
generated using SuperScriptIII Reverse Transcriptase (Invitrogen). To
validate our hepatocyte results, a commercially available cDNA
generated from human hepatocytes was also purchased (Caltag Med-
systems) and analyzed for CD151 expression. Assessment of mRNA
expression levels was performed via quantitative real-time PCR (qRT-
PCR), using predesigned TaqMan Gene Expression Assays (Applied
Biosystems) and 2 TaqMan Universal PCR Master Mix (Applied
Biosystems). qRT-PCR was performed on a Lightcycler 480 (Roche)
using the following cycling conditions: 95°C for 10 min followed by
45 cycles of 95°C for 10 s, 60°C for 1 min, 72°C for 1 s. Samples were
run in triplicate with average cycle threshold (Ct) values for CD151
normalized against an appropriate housekeeping gene. Different
housekeeping genes were used in separate experiments to ensure a
consistent expression across the disease states or cell treatments being
studied. Primers used are listed in Table 2.
Western blot analysis. A sample (~75 mg) of liver tissue was
homogenized in 1.5 ml CelLytic MT lysis buffer (Sigma-Aldrich)
with 1% protease inhibitor cocktail (Sigma-Aldrich), 1% phosphatase
inhibitor cocktail 3 (Sigma-Aldrich), and 5 U/ml DNase-I (Sigma-
Aldrich), using gentleMACS M-tubes (Miltenyi Biotec). Lysate pro-
tein concentrations were calculated and normalized using the bicin-
choninic acid assay (Sigma-Aldrich) per standard protocols, with BSA
(Sigma-Aldrich) utilized as a protein standard. Twenty micrograms of
protein lysate was resolved via SDS-PAGE on a 12% polyacrylamide
gel and subsequently transferred to a nitrocellulose membrane
(ThermoFisher Scientific) by semi-dry transfer using the Trans-Blot
Turbo Transfer System (Bio-Rad). Following transfer, membranes
were blocked in 5% nonfat milk (Marvel) in TBS/0.1% Tween
(TBST) for 1 h at room temperature. Primary antibodies (CD151; Abd
Serotec; 1.4 g/ml and -actin; Sigma-Aldrich; 1 in 1,000 dilution),
diluted in TBST with 3% BSA (GIBCO by Life Technologies) and
0.1% azide (Sigma-Aldrich) were then added to the membranes and
incubated overnight at 4°C. Secondary antibodies [goat anti-mouse
horseradish peroxidase (HRP); Dako; 0.14 g/ml and goat anti-mouse
IRDye 680LT; LI-COR; 0.14 g/ml] were diluted in 5% nonfat milk
and added for 60 min at room temperature. Finally the membranes
were developed with enhanced chemiluminescent substrate (ECL;
Pierce) and Amersham Hyperfilm MP (GE Healthcare) or, where
Table 1. Monoclonal antibodies: clone, source, and final concentration
Monoclonal Antibodies Clone Source Final Concentration, g/ml
Mouse negative control DAK-GO1 DAKO 6.7
Mouse negative control DAK-GO5 DAKO 5.0
Mouse negative control DAK-GO9 DAKO 5.0
Mouse anti-human CD151 IIG5a Abd Serotec 6.7
Mouse monoclonal anti-actin -smooth muscle 1A4 Sigma-Aldrich 5.0
Mouse monoclonal anti-human CD68 Y1/82A BD Biosciences 5.0
Mouse monoclonal anti-human CD90 SE10 eBioscience 1.0
Mouse monoclonal anti-human CD31 JC70A DAKO 5.0
Mouse monoclonal anti-human CD34 QBEND/10 Abd Serotec 5.0
Mouse monoclonal anti-human CD3 UCHT1 eBioscience 4.0
Mouse monoclonal anti-human EpCAM HEA 125 Progen Biotechnik 5.0
Mouse monoclonal anti-human CK18 DC10 DAKO 1.0
Mouse anti-human early endosomes (EEA-1) 14 BD Biosciences 5.0
Mouse anti-human cis-Golgi (GM130) 35 BD Biosciences 5.0
Mouse anti-human lysosome (LAMP-1) 25 BD Biosciences 5.0
Mouse anti-human VCAM-1 BBA5 R&D Systems 5.0
Alexa Fluor 546 goat anti-mouse IgG2a — Life Technologies 8.0
Alexa Fluor 546 goat anti-mouse IgG2b — Life Technologies 8.0
Alexa Fluor 546 goat anti-rat IgG2a — Life Technologies 8.0
EpCAM, epithelial cell adhesion molecule.
Table 2. Target and TaqMan assay identification
Target TaqMan Assay ID
CD151 Hs00911635_g1
GAPDH Hs99999905_m1
18S Hs99999901_s1
GUSB Hs00939627_m1
-Actin Hs01060665_g1
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IRDye secondary antibodies were used, scanned on an Odyssey
Imaging System (Li-COR Biosciences). Semiquantitative analysis of
protein bands was performed on ImageJ software, with CD151 ex-
pression shown relative to the housekeeping protein, -actin.
Stimulation of HSECs. HSECs were stimulated with a range of
cytokines and growth factors. In each case, cells were incubated in
SFM with 10% FCS for 24 h before respective stimuli were added for
the subsequent 24 h. Where HepG2 supernatant was used to stimulate
HSECs, HepG2 cells were grown to confluence in DMEM with 10%
FCS before the media was exchanged for SFM with 10% FCS for
24 h. The resultant supernatant was then used to stimulate primary
HSEC cultures for 24 h. Control isolates consisted of HSECs main-
tained in human endothelial SFM with 10% FCS for 24 h. Growth
factors (VEGF and HGF) and proinflammatory cytokines (TNF- and
IFN-) used in HSEC stimulation experiments were used at a con-
centration of 10 ng/ml and purchased from Peprotech.
HSECs in hypoxia. Where the effect of hypoxic conditions on
CD151 expression in HSECs was investigated, HSEC media was
degassed for 24 h in a Whitley H35 hypoxystation hypoxic chamber
(Don Whitley Scientific) at 1% O2 before HSECs were incubated in
the chamber with the degassed media for 24 h. Cells were then fixed
in cold methanol in the chamber and subsequently analyzed via
ELISA (see Cell-based ELISA below).
Cell-based ELISA. HSECs were grown to confluence in rat tail
collagen-coated 96-well plates (Corning CoStar) and then stimulated
(see Stimulation of HSECs), before being fixed in 100% methanol and
washed with a buffer solution of PBS with 0.1% BSA (Sigma-
Aldrich). Cells were then blocked for nonspecific antibody binding in
PBS with 2% goat serum diluted for 45 min. Primary antibody
(CD151; Abd Serotec; 5 g/ml) or mouse IgG1 negative control
(clone DAK-GO1 DAKO; 5 g/ml) were added to the appropriate
wells and incubated for 60 min at room temperature. This was
followed by washing with PBS/BSA solution and then the addition of
goat anti-mouse HRP-conjugated secondary antibody (Dako; 0.2
g/ml) to each well for 45 min. The cells were then washed again with
PBS/BSA before developing with an OPD substrate (1,2-phenylene-
diamine dihydrochloride tablets; Dako) dissolved in distilled water
with 2.5 l of 30% H2O2. The reaction was arrested with a stop
solution of 0.5 M H2SO4 (Sigma-Aldrich) before absorbance was
measured on a Synergy HT automated microplate reader (BioTek) at
490 nm. Mean absorbance values were calculated from triplicate wells
and corrected for background absorbance by subtracting absorbance
values obtained from triplicate wells of an isotype-matched negative
control antibody.
Immunocytochemistry. For immunofluorescent staining of HSECs,
cells were grown to confluence on rat tail collagen-coated eight-well
glass-bottom -slides (Ibidi), stimulated (see Stimulation of HSECs)
and subsequently fixed in 100% methanol. The cells were then
blocked and permeabilized with a solution of PBS with 10% goat
serum, 2 casein, and 0.1% Triton-X 100 (Sigma-Aldrich) for 20 min
at room temperature. Primary antibodies, diluted in blocking buffer,
were then added and incubated for 60 min, followed by isotype-
specific fluorescence-conjugated goat anti-mouse secondary antibod-
ies for 30 min. Finally, 300 nM DAPI was added to each chamber for
2 min before the mounting in aqueous Fluorescent Mounting Medium
(Dako). All immunofluorescent staining was imaged on a Carl Zeiss
LSM780 Zen Confocal microscope (Carl Zeiss) and analyzed by LSM
software.
Peripheral blood lymphocyte isolation. Blood samples were taken
from patients undergoing venesection for hemochromatosis, which we
have previously used for lymphocyte migration assays (33). Lympho-
cytes were isolated by density-gradient centrifugation over Lympho-
lyte (Cedarlane Laboratories) for 25 min at 800 g, before platelet and
monocyte depletion. These steps ensure highly pure populations of
peripheral blood lymphocytes (PBLs) as previously described (22).
These cells were washed and resuspended in RPMI 1640 containing
10% FCS.
Static adhesion assays. Tissue sections from explant livers from
alcoholic liver disease, primary sclerosing cholangitis, primary biliary
cholangitis, and samples of normal liver from resections were initially
incubated with blocking antibody to CD151 (IIG5a; AbD Serotec; 10
g/ml) or control antibody. The sections were then overlaid with
PBLs that had been prelabelled with cell tracker green (ThermoFisher
Scientific); PBLs were resuspended at 1  106/ml, and 100-l
aliquots were added to each section for 30 min at room temperature to
adhere in static conditions. The nonadherent cells were removed, and
the remaining adherent cells were fixed with acetone. The sections
were then stained with DAPI and imaged on a Carl Zeiss LSM780
Zen Confocal microscope (Carl Zeiss), and lymphocytes present in a
minimum of 10 representative high-power fields per section were
counted.
Flow-based adhesion assays. In vitro flow-based adhesion assays
previously described by our laboratory were used to investigate the
role of CD151 on HSECs under conditions of physiological flow (32).
Briefly, HSECs were seeded in channels of rat tail collagen-coated 0.4
Channel -Slides VI (Ibidi) and cultured to confluence overnight.
Cells were then stimulated with TNF- for 24 h to promote adhesion
receptor expression. A sample (1  106 cells/ml) of PBLs, in flow
media comprising RPMI with 0.1% BSA, was then perfused over the
HSECs at a physiological shear stress of 0.05 Pa. Each chamber of the
microslides was perfused for 5 min with PBLs before 5 min of wash
with the flow media alone. The subsequent adherent and migratory
cells were then imaged by phase-contrast microscopy with an Olym-
pus IX50 Inverted Microscope (Olympus) connected to an image
capture device, with video recordings of 12 frames from each chamber
taken. Blinded analysis was then performed for quantification of the
number of adherent or transmigrated PBLs. The number of adherent
cells were normalized to cells per square millimeter per 106 cells
perfused, and the number of transmigrated cells was expressed as a
percentage of total adherent cells. The addition of blocking antibodies
to CD151 (IIG5a; AbD Serotec; 10 g/ml), VCAM-1 (BBA5; R&D
Systems; 10 g/ml), or isotype-matched negative control antibodies
were performed immediately preceding each assay. Each antibody
was diluted in flow media before 50 l was added to each chamber
and incubated for 30 min before initiation of the flow assay.
siRNA knockdown of CD151 in HSECs. Cells were transiently
transfected with 25 nM HsCD151_5 Flexitube siRNA (S102777250;
QIAGEN) or a nontargeting siRNA control (negative control siRNA;
QIAGEN), using Lipofectamine RNAiMAX Transfection Reagent
(Invitrogen). Briefly, 2.5  105 or 7.5  104 HSECs were seeded in
rat tail collagen-coated six-well culture plates or 0.4 Channel -Slides
VI (Ibidi), respectively, and grown to confluence overnight. Subse-
quently, siRNA duplexes diluted in Opti-MEM (GIBCO by Life
Technologies) were mixed with a final concentration of 0.3% Lipo-
fectamine RNAiMAX and incubated for 10 min at room temperature.
Cells were then washed twice with PBS, and the duplex/Lipo-
fectamine RNAiMAX mixture was added to the cells and incubated
for 4 h at 37°C. The duplex/Lipofectamine RNAiMAX mixture was
then removed from the cells and replaced with HSEC medium without
antibiotics and cultured as normal. After 24 h, transfected cells were
stimulated with 10 ng/ml TNF- and left for a further 24 h. HSECs
cultured in six-well culture plates were harvested in CelLytic MT lysis
buffer with 1% protease inhibitor, 1% phosphatase inhibitor cocktail
3, and 5 U/ml DNase-I, and CD151 knockdown was confirmed via
Western blot analysis (see Western blot analysis above). HSEC-
cultured 0.4 Channel -Slides VI were used in flow-based adhesion
assays (see Flow-based adhesion assays above).
Statistical analysis. All results are presented as means  SE or
median value  interquartile range (IQR) where the data form a
nonparametric distribution. Statistics were performed on Prism 6.0
software (GraphPad), with Student’s t-tests (parametric) and Mann-
Whitney U-tests (nonparametric) used to compare statistical signifi-
cance between two groups. One-way ANOVA with post hoc Tukey’s
(parametric) test and Kruskall-Wallis one-way ANOVA with post hoc
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Fig. 1. CD151 expression is upregulated in chronic diseased livers and hepatocellular cancer. A: immunohistochemical staining of CD151 (brown) in
representative examples of normal liver (NL), primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), autoimmune hepatitis (AIH), alcoholic
liver disease (ALD), and nonalcoholic steatohepatitis (NASH). B: surface area quantification of immunohistochemical staining in parenchymal and fibrotic
regions; n 	 4 in each group. C: Western blot analysis of CD151 in normal liver and chronic liver disease (CLD) samples. D: immunohistochemical staining
(brown) of CD151 in liver sinusoids and in precirrhotic liver sections in patients with PSC. E: immunohistochemical staining (brown) of CD151 in tumor core
and tumor margin in a representative case of hepatocellular carcinoma (HCC). F: Western blot analysis of CD151 in normal liver and HCC samples. *P 
 0.05,
***P 
 0.005; bar 50 	 m (D, left), 200 m (A; D, middle and right; and E).
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Dunn’s test (nonparametric) were also used when comparison be-
tween multiple groups was required. Values of P 
 0.05 were
considered statistically significant.
RESULTS
CD151 is upregulated in chronic liver disease and hepato-
cellular cancer. Immunohistochemical analysis of normal and
diseased human liver tissue revealed that CD151 localized to
the hepatic sinusoids and major vasculature with only weak
expression on bile ducts and hepatocytes (Fig. 1A). Although
expression of CD151 in the liver parenchyma was similar in
normal and diseased states, more CD151 was detected in
fibrotic septa (Fig. 1, A and B), with particularly strong expres-
sion on scar-associated vessels. Western blotting confirmed
upregulation of CD151 at the protein level in diseased tissue.
(Fig. 1C). Additional staining of liver sections from patients
with earlier stages of fibrosis demonstrated strong expression
of CD151 on the sinusoids, and we also noted upregulation of
CD151 in areas of fibrosis (Fig. 1D).
Primary human HCC tumor tissue stained positive for
CD151 throughout the tumor sinusoids, on the tumor-associ-
ated vasculature, and on the tumor cells themselves (Fig. 1E).
Also, at the tumor margin, CD151 expression was evident
within the tumor capsule and on capsule-associated vessels
(Fig. 1E). Increased tumoral expression of CD151 was con-
firmed by Western blot analysis (Fig. 1F).
CD151 is expressed predominantly in HSECs and neoves-
sels in chronic liver disease. Dual-color immunofluorescent
colocalization was used to determine cell-specific expression
of CD151 in normal and chronically diseased (ALD and PSC)
liver tissues. CD151 was found to colocalize with the endo-
thelial marker CD31 within the sinusoids (Fig. 2A) but not
CD68-positive Kupffer cells (Fig. 2B). CD151 expression also
demonstrated weak colocalization with the hepatocyte marker
CK18 and biliary epithelial cell adhesion molecule (Fig. 2, C
and D). Furthermore, CD151 was not expressed by activated
stellate cells (-smooth muscle actin-positive; Fig. 2E) but was
associated with CD34-positive cells in tissue taken from chron-
ically inflamed livers (Fig. 2F), indicating expression by vas-
cular endothelium and neovessels at sites of inflammation and
fibrotic septa.
We next isolated primary human liver cell populations from
fresh tissue, including PHHs, HSECs, BECs, HSCs, and
aLMFs. We found that CD151 expression at the transcript level
was similar between HSECs and hepatocytes but significantly
higher compared with the other cell types (Fig. 3A). We have
previously shown that sinusoidal endothelial cells isolated
from human liver tissue maintain their distinct phenotype
typified by high scavenger receptor expression and atypical
junctions compared with conventional endothelium (29). These
cells were isolated from various diseases and stages of liver
disease; however, detailed analysis shows that in culture each
isolate is phenotypically very similar with comparable expres-
sion levels of adhesion receptors and junctional molecules
(29). Confirmation of the phenotype and purity of HSECs were
determined by rapid uptake of FITC-FSA. Our isolation
method routinely provided a sinusoidal endothelial purity of
85% of cells, with all cells expressing CD31 as determined
by flow cytometry (Fig. 3B and MATERIALS AND METHODS).
Immunofluorescent staining of CD151 in HSECs showed that
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Fig. 2. CD151 colocalizes to endothelial markers within the hepatic sinusoids and on neo vessels in the fibrotic septum. A–C: dual-color immunofluorescent
staining of liver tissue samples from normal liver and chronically inflamed livers (ALD and PSC) for CD151 (green) with endothelial marker CD31 (A),
macrophage marker CD68 (B), hepatocyte marker CK18 (C). D–F: dual-color immunofluorescent staining of liver tissue samples of chronically inflamed livers
(ALD and PSC) for CD151 (green) with biliary epithelial cell adhesion molecule (EpCAM) (D), fibroblast marker -smooth muscle actin (SMA) (E), and
neovessel marker CD34 (F). G–I: dual-color immunofluorescent staining of liver tissue sample isotype-matched controls. Bar 	 50 m.
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CD151 colocalized with early endosomes, Golgi apparatus,
and lysosomes (EEA-1, GM130, and LAMP-1, respectively)
(Fig. 3, C–E). These results suggest that CD151 undergoes
continual cell cycling in HSECs, with its posttranslational
modification in the Golgi apparatus before transportation to the
cell surface via endosomes and subsequent degradation within
lysosomes.
Regulation of CD151 in HSECs. Having detected increased
endothelial expression of CD151 at sites of chronic liver
injury, we assessed the regulation of the protein on HSECs by
proinflammatory cytokines (TNF- and IFN-) and the fibro-
genic cytokine, IL-13. Stimulation with these cytokines did not
alter the expression of CD151 in HSECs (data not shown).
Chronic fibrosis is also associated with increased transforming
growth factor  (TGF-) activity (30) and tissue hypoxia,
which contributes to angiogenesis (28), leading us to study the
effect of prolonged TGF- stimulation as well as culture under
hypoxic conditions on expression of CD151 by HSECs. We
did not detect any increase in CD151 protein expression with
TGF- stimulation or hypoxia (Fig. 4, A and B). Previously,
A B
C
D
E
CD151 EEA-1 Overlay
CD151
CD151
GM130 Overlay
OverlayLAMP-1
FITC-FSA 
Fig. 3. CD151 is highly expressed in isolated
primary human liver sinusoidal endothelial
cells. A: mRNA levels of CD151 in popula-
tions of isolated primary human hepatocytes
(PHH), human hepatic sinusoidal endothelial
cells (HSEC), biliary epithelial cells (BEC),
hepatic stellate cells (HSC), and activated
liver myofibroblasts (aLMF). B: confocal
microscopy of HSECs after incubation with
FITC-FSA for 15 min. Inset: control cells.
C–E: dual-color immunofluorescent staining
of HSECs for CD151 (green) and early en-
dosome marker (EEA-1) (C), Golgi marker
GM130 (D), and lysosome marker LAMP-1
(E). Bar 	 20 m (B), 15 m (C–E). **P 

0.01.
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our group has shown that growth factors can increase the
expression of atypical adhesion receptors, such as CLEVER-
1/stabilin-1 (33). Stimulation with growth factors involved in
angiogenesis, HGF and VEGF, led to a statistically significant
increase in expression of CD151 protein with VEGF stimula-
tion; there was no additional increase in expression with the
combination of growth factors (Fig. 4C). We detected endo-
thelial CD151 at high levels on HCC tumor vessels and in
vessels within the stroma surrounding the tumor (Fig. 1C),
leading us to hypothesize that factors produced locally by the
tumor may promote CD151 expression. To study this, HSECs
were incubated with supernatant from an HCC cell line
(HepG2), which led to significant upregulation of CD151
expression in HSECs compared with basal conditions, which
was greater than that observed for treatment with HGF and
VEGF (Fig. 4D).
CD151 is a regulator of VCAM-1-mediated adhesion of
lymphocytes to HSECs. Modified Stamper-Woodruff tissue
binding assays on diseased liver tissue demonstrated that lym-
phocytes bound to the fibrotic septa where we had shown
CD151 was upregulated, as well as within the sinusoidal
channels throughout the parenchyma (Fig. 5A). Antibody
blockade of CD151 significantly inhibited lymphocyte adhe-
sion to human liver tissue compared with an isotype-matched
control (Fig. 5B). Lymphocyte recruitment in the hepatic sinu-
soids is selectin independent, and a major role in lymphocyte
capture and adhesion to HSECs is played by VCAM-1 (23, 37).
Subsequent transmigration is a multistep process involving
ICAM-1, VAP-1, and stabilin-1 (23, 33, 37). Previous studies
have reported that CD151 is associated with VCAM-1 and
ICAM-1 (5), leading us to look for colocalization of CD151 with
VCAM-1 in HSECs. We were able to show CD151 colocalization
with VCAM-1 in stimulated HSECs both at the cell membrane
and within intracellular compartments (Fig. 5C).
To understand the role of CD151 in the adhesion cascade
during lymphocyte recruitment to the liver, we performed
lymphocyte-endothelial adhesion assays under physiologically
relevant flow rates and determined the effect of blocking
CD151 and VCAM-1 both independently and in combination.
Blockade of CD151 alone led to a significant reduction in total
lymphocyte adhesion to HSECs (Fig. 6A), reducing adhesion to
levels similar to those observed for blockade of the typical
adhesion molecule, VCAM-1. However, blocking both recep-
tors did not reduce adhesion, further suggesting that CD151
cooperates with VCAM-1 to regulate lymphocyte adhesion to
HSECs (Fig. 6A). We used phase-contrast microscopy during
the flow adhesion assay to determine the proportion of lym-
phocytes adherent to the surface of the endothelial cells and
those that had migrated underneath the endothelial monolayer
(32). CD151 blockade did not inhibit the proportion of cells
migrating underneath the endothelial monolayer, suggesting
that it does not contribute to the transendothelial migration step
in lymphocyte recruitment across HSECs (Fig. 6B). As an
alternative to antibody blockade, we also inhibited CD151
function by knocking down expression with siRNA (Fig. 6C).
We achieved ~60% knockdown of CD151 (Fig. 6D), and
repeat flow assays confirmed a functional role for CD151 in
lymphocyte adhesion to HSECs (Fig. 6E). Once again, CD151
inhibition and VCAM-1 blockade had similar effects on reduc-
ing adhesion, with no additional inhibition when CD151
knockdown and VCAM-1 blockade were combined (Fig. 6E).
Using a fixed cell technique with confocal microscopy and
immunofluorescent staining that we recently described (33),
we visualized cellular CD151 on HSECs in relation to lym-
phocyte binding from flow. CD151 enrichment was seen
around adherent CD3 lymphocytes, consistent with a role of
CD151 in immune cell recruitment (Fig. 6F).
DISCUSSION
Tetraspanins are a family of proteins that contribute to
several aspects of cell-cell interactions. CD151 is involved in
Fig. 4. CD151 is upregulated by growth
factors and supernatant from hepatocellular
cancer cell line. Expression of CD151 by
ELISA in HSECs treated with transforming
growth factor- (TGF-) (A). Each sample
was run in triplicate; n 	 3. B: expression of
CD151 by ELISA in HSECs cultured in
normoxic and hypoxic conditions; n 	 6. C:
expression of CD151 by ELISA in HSECs
treated with hepatocyte growth factor (HGF)
and VEGF with each sample run in triplicate;
n 	 6. D: expression of CD151 by ELISA in
HSECs treated with HepG2 supernatant with
each sample run in triplicate; n 	 4. *P 

0.05.
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cell-to-cell communication, wound healing, platelet aggrega-
tion, cell trafficking, and angiogenesis (7, 15, 34, 38). In
addition, it has been reported to play a role in leukocyte
adhesion to human umbilical vein endothelial cells. To our
knowledge, a role for CD151 in leukocyte recruitment to
specialized vascular beds has not been investigated. A key step
in leukocyte recruitment to the liver is binding to HSECs.
These endothelial cells have a distinct phenotype compared
with conventional venular endothelium determined by the
functional requirements of their microenvironment (9, 14). We
have previously shown that, following isolation from human
liver tissue, these endothelial cells maintain their unique phe-
notype and junctional complexes as well as their functional
characteristics (29). In the present study, we have characterized
the expression of CD151 in normal and diseased human liver
and found it to be upregulated at sites of leukocyte recruitment,
including the hepatic sinusoids and neovessels of the fibrous
septa as well as on vessels in HCC and surrounding peritu-
moral stroma. Isolated HSECs maintain expression of CD151,
allowing us to study the regulation and function of CD151 in
these cells. Detailed analysis of CD151 cellular distribution
suggests that it is mobilized to the cell surface from intracel-
lular vesicles, and, although we detected the protein at chronic
inflammatory sites in vivo, expression of CD151 was not
regulated in vitro by the proinflammatory cytokines TNF- or
IFN- in contrast to many of the standard endothelial adhesion
receptors. Previous studies on epithelial cells have demon-
strated that CD151 is upregulated by chronic exposure to
TGF- (hepatocyte cell line) (17) and suppressed by hypoxia
(colon cancer cell line) (12). In our study, neither stimulation
of HSECs with TGF- nor exposure to hypoxia altered CD151
expression, suggesting that the regulation of CD151 differs
between endothelial cells and epithelial cells. However, ex-
pression was increased by treatment with growth factors,
specifically VEGF, and by culture in culture supernatant from
an HCC cell line. These findings suggest that CD151 in
endothelial cells is regulated by microenvironmental signals
induced by tissue remodeling or those present in the tumor
microenvironment.
We then demonstrated that CD151 mediates lymphocyte
adhesion to human liver tissue and to HSECs under flow.
CD151 was closely associated with VCAM-1 on HSECs, and
CD151 VCAM-1 Overlay
C
A B
Static Adhesion
Fig. 5. CD151 mediates lymphocyte binding to human liver tissue and colocalizes with VCAM-1 in primary human liver endothelium. A: representative low-
and high-power images of static Stamper–Woodruff adhesion assays of cell tracker green-labeled peripheral blood lymphocytes binding to human liver tissue
demonstrating adhesion to the sinusoidal regions within the liver parenchyma; cell nuclei were stained with DAPI. Dashed lines outline a fibrous septum, and
arrows highlight lymphocytes within the parenchyma. B: sections were treated with anti-CD151 antibody or appropriate class-matched control antibody, and the
results of 4 independent experiments are shown as the number of adherent cells per low-power image. C: dual-color immunofluorescent staining of TNF--treated
HSECs with CD151 (green), VCAM-1 (red), and DAPI (nucleus, blue). Insets: background fluorescence for each class-matched control antibody. Bar	 200 m
(A), 50 m (B), 10 m (C). *P 
 0.05.
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the fact that functional blockade of VCAM-1 and CD151 in
combination was not additive suggests that CD151 mediates
lymphocyte adhesion to HSECs through its interaction with
VCAM-1. Stereotactical interference of CD151 blocking anti-
body on lymphocyte binding to VCAM-1 was ruled out by
demonstrating that CD151 knockdown by siRNA also signif-
icantly inhibited lymphocyte binding to HSECs.
Together, these results suggest that CD151 may play a
particular role in maintaining lymphocyte recruitment in
chronic liver injury, leading to persistent inflammation and
ongoing tissue damage and fibrogenesis. This makes CD151 a
possible therapeutic target for inflammatory liver disease. De-
spite the growing global burden of chronic inflammatory liver
disease, treatment strategies mainly rely upon removal of the
underlying causative agent or transplantation for end-stage
disease. By interfering with the ability of CD151 to maintain
lymphocyte recruitment in chronic liver disease, it may be
possible to switch off persistent inflammation, leading to res-
olution. Tetraspanin interactions can affect heterotypic partner
protein receptor avidity, as shown by Ke et al. (18), who used
an antibody to dissociate CD151 from an integrin partner
protein, which prevented tumor progression. VCAM-1 is a
receptor that is not restricted to endothelial cells but also found
on stromal cells and epithelial cells, where it can regulate
lymphocyte adhesion and survival (2, 27, 35). Thus modulating
CD151 interactions with VCAM-1 in endothelial cells may be
an attractive and specific target for chronic inflammatory liver
disease. Our observations that CD151 is broadly upregulated in
HCC and that factors secreted by HCC can induce expression
on endothelium suggest that it may have an important role in
Fig. 6. CD151 mediates the adhesion of peripheral lymphocytes to HSECs under conditions of shear stress. A: quantification of adherence of lymphocytes to
monolayers of HSECs in flow assays pretreated with isotype-matched control (IMC) and CD151, VCAM-1, and a combination of CD151/VCAM-1-blocking
antibodies; n 	 3 independent experiments with different HSECs. B: proportion of adherent cells that underwent transendothelial migration after blockade with
IMC, CD151, VCAM-1, and a combination of CD151/VCAM-1; n 	 3 independent experiments with different HSECs. C: representative Western blot analysis
of CD151 in HSECs treated with control and CD151 siRNA knockdown. D: quantification of CD151 expression in HSECs treated with siRNA knockdown of
CD151 expressed as a % of expression in control HSECs; n 	 4 independent experiments with different HSECs. E: quantification of adherence of lymphocytes
to monolayers of HSECs in flow assays pretreated with control siRNA and CD151 siRNA, VCAM-1, and a combination of CD151/VCAM-1-blocking antibodies;
n 	 4 independent experiments with different HSECs. F: representative confocal image of CD151 (red) accumulation around a CD3-positive lymphocyte (blue)
firmly adherent to cell tracker green-labeled HSECs. Bar 	 5 m, *P 
 0.05, **P 
 0.01.
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hepatic tumorigenesis. What role CD151 plays is presently
unclear. It could promote tumorigenesis as a consequence of
establishing persistent chronic inflammation, or, as has been
reported in other systems, it may promote the growth and
spread of tumor cells. Finally, by modulating lymphocyte
recruitment, it may alter the immune response to the tumor. It
is also now well accepted that the immune system and immune
cell recruitment make a major contribution to the development
and prognosis of HCC, with immunotherapy already com-
menced in clinical trials (25). Thus we propose that CD151
could be targeted to inhibit lymphocyte recruitment to the liver
and prevent the progression of inflammatory liver diseases to
end-stage fibrosis and reduce the risk of HCC.
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